[
  {
    "text": "3.19 Exclusivity Commitment of SFJ. During the applicable Exclusive Period, SFJ shall not, and shall cause its Affiliates",
    "bbox": [
      179,
      97,
      1000,
      111
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "not to, either by itself or through a Third Party, conduct human clinical trials of, or sell, offer for sale or have sold:",
    "bbox": [
      112,
      117,
      1000,
      130
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "3.19.1 any Competing Product (other than Product) alone or in combination (whether fixed dose or co-packaged)",
    "bbox": [
      247,
      152,
      1000,
      167
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "with one (1) or more other active ingredients;",
    "bbox": [
      114,
      172,
      494,
      186
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "3.19.2 any combination (whether fixed dose or co-packaged) with one (1) or more other active ingredients of the",
    "bbox": [
      247,
      206,
      1000,
      221
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Product and a Competing Product;.",
    "bbox": [
      111,
      227,
      410,
      242
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "3.19.3 any agent that is intended as an antidote to, or is intended to neutralize, abrogate or reverse the antiplatelet",
    "bbox": [
      247,
      261,
      1000,
      276
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "activity of, (i) any Brilinta Competing Product alone or in combination (whether fixed dose or co-packaged) with one (1) or more",
    "bbox": [
      114,
      283,
      1000,
      295
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "other active ingredients or (ii) both the Ticagrelor Compound and a Brilinta Competing Product;.",
    "bbox": [
      112,
      300,
      922,
      316
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "3.19.4 without limitation to the foregoing, any agent with dual activity as (i) an antidote to, or for use as an agent to",
    "bbox": [
      246,
      335,
      1000,
      351
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "neutralize, abrogate or reverse the antiplatelet activity of, the Ticagrelor Compound and (ii) an antidote to, or for use as an agent to",
    "bbox": [
      112,
      357,
      1000,
      370
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "neutralize, abrogate or reverse the antiplatelet activity of, any Brilinta Competing Product; or.",
    "bbox": [
      111,
      375,
      893,
      390
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "3.19.5 any Brilinta Competing Product..",
    "bbox": [
      248,
      409,
      579,
      424
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "3.20 Program Transfer. In the event that, at any time after payment to PB of the Initial Development Cost Payment on the.",
    "bbox": [
      180,
      446,
      1000,
      460
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Initial Funding Date, PB shall (a) fail to pay any amounts payable to SFJ hereunder within [***] of the date such payment is due,",
    "bbox": [
      110,
      465,
      1000,
      481
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "or (b) become in default of its obligations under the AZ License (excluding (x) any such default that would not entitle AZ to",
    "bbox": [
      111,
      484,
      1000,
      500
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "terminate the AZ License and (y) any such default that is caused by SFJ's breach of its obligations under this Agreement), or (c) (i).",
    "bbox": [
      111,
      504,
      1000,
      518
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "fail to remedy the Going Concern Condition within the Going Concern Cure Period as set forth in Section 3.18.3 or (ii) refuse to",
    "bbox": [
      112,
      523,
      1000,
      537
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "accept the Going Concern Funding if offered by SFJ as set forth in Section 4.2.4, then, SFJ may deliver written notice to PB.",
    "bbox": [
      111,
      541,
      1000,
      556
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "electing to cause PB's business related to the Product to be transferred to SFJ (the \"Program Transfer Notice'), and shall deliver a",
    "bbox": [
      113,
      561,
      1000,
      574
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "copy of the Program Transfer Notice to MedImmune concurrently with delivery to PB, and within [***] following the delivery of",
    "bbox": [
      111,
      579,
      1000,
      594
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "the Program Transfer Notice, PB and SFJ shall execute and deliver a Program Transfer Agreement in the form attached hereto as",
    "bbox": [
      113,
      599,
      1000,
      612
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Exhibit O (the \"Program Transfer Agreement') which shall effect the Program Transfer effective as of the date SFJ delivers the",
    "bbox": [
      112,
      618,
      1000,
      632
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Program Transfer Notice to PB. For clarity, this Section 3.20 shall not be effective prior to payment to PB of the Initial.",
    "bbox": [
      113,
      637,
      1000,
      650
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Development Cost Payment on the Initial Funding Date..",
    "bbox": [
      113,
      657,
      582,
      669
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "ARTICLE 4",
    "bbox": [
      608,
      691,
      722,
      703
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "DEVELOPMENT COSTS",
    "bbox": [
      542,
      730,
      790,
      742
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "4.1 Development Costs. SFJ will be obligated to pay or incur up to One Hundred Twenty Million U.S. Dollars",
    "bbox": [
      179,
      781,
      1000,
      795
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "($120,o00,o00.00) of Development Costs (\"Maximum Development Costs') in accordance with the funding schedule set forth in.",
    "bbox": [
      113,
      800,
      1000,
      815
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Section 4.2. Any",
    "bbox": [
      111,
      817,
      256,
      835
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
    "bbox": [
      133,
      1000,
      621,
      1000
    ],
    "label": 38,
    "category": "Insurance"
  }
]